Background: Although crackles on chest auscultation represent a fundamental component of the diagnostic suspect for fibrotic interstitial lung disease (ILD), their reliability has not been properly studied. We assessed the agreement among respiratory physicians on the presence and changes over time of audible crackles collected in a prospective longitudinal cohort of patients with fibrotic ILD.
Methods: Lung sounds were digitally recorded at baseline and after 12 months at eight anatomical sites.
Real-world data on the long-term effectiveness of the anti-IL17 agent secukinumab in treating moderate-to-severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate-severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12-week intervals.
View Article and Find Full Text PDFExpert Opin Pharmacother
April 2024
Introduction: Following the INPULSIS and ASCEND studies, leading to the first two approved antifibrotic therapies for patients with IPF, ongoing investigations are firmly exploring novel agents for a targeted effective and better tolerated therapy able to improve the natural history of the disease.
Areas Covered: This review aims to analyze recent advances in pharmacological research of IPF, discussing the currently available treatments and the novel drugs under investigation in phase 3 trials, with particular emphasis on BI 1015550 and inhaled treprostinil. The literature search utilized Medline and Clinicaltrials.
A straightforward synthesis of a series of hybrid organic-inorganic materials (HOIMs) containing imidazolium moieties was achieved. The preparation of the imidazolium acetate precursor was performed in a single-step procedure using the Debus-Radziszewski reaction. The as-synthesized alkoxysilane was employed in combination with tetraethyl orthosilicate to generate an HOIM presenting a high specific surface area.
View Article and Find Full Text PDF